Varenicline for smoking cessation in bipolar disorder: A randomized, double-blind, placebo-controlled study

Journal of Clinical Psychiatry

Volumn 75, Issue 7, 2014, Pages 765-772

  Chengappa, K N Roy ^a   Perkins, Kenneth A ^a   Brar, Jaspreet S ^a   Schlicht, Patricia J ^a   Turkin, Scott R ^b   Hetrick, Michelle L ^b   Levine, Michele D ^a   George, Tony P ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b DuBois Regional Medical Center   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CARBON MONOXIDE; LAMOTRIGINE; LITHIUM; PLACEBO; VALPROIC ACID; VARENICLINE;

ABDOMINAL PAIN; ABNORMAL DREAMING; ADULT; AGED; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ASTHENIA; BEDTIME DOSAGE; BIPOLAR DISORDER; BODY WEIGHT DISORDER; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DSM-IV; DYSPEPSIA; DYSPNEA; EVENING DOSAGE; EXHALATION; FATIGUE; FEMALE; FLATULENCE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; INCREASED APPETITE; INSOMNIA; LETHARGY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; MORNING DOSAGE; MOTIVATION; NAUSEA; OUTCOME ASSESSMENT; PATIENT COUNSELING; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCORING SYSTEM; SELF REPORT; SMOKING CESSATION; SMOKING HABIT; SOMNOLENCE; SUICIDAL IDEATION; TASTE DISORDER; TOBACCO DEPENDENCE; TREATMENT DURATION; URINARY TRACT INFECTION; VOMITING; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; BENZAZEPINES; BIPOLAR DISORDER; COMORBIDITY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINIC AGONISTS; QUINOXALINES; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 84905216717     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13m08756     Document Type: Article

References (52)

1. Centers for Disease Control and Prevention (CDC). Vital signs: current cigarette smoking among adults aged ≥ 18 years with mental illness - United States, 2009-2011. MMWR Morb Mortal Wkly Rep. 2013;62(5):81-87. PubMed
2. Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284(20):2606-2610. doi:10.101/jama.284.20.2606 PubMed
3. Hughes JR, Hatsukami DK, Mitchell JE, et al. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry. 1986;143(8):993-997. PubMed (Pubitemid 16073948)
4. Itkin O, Nemets B, Einat H. Smoking habits in bipolar and schizophrenic outpatients in southern Israel. J Clin Psychiatry. 2001;62(4):269-272. doi:10.408/JCP.v62n0409 PubMed (Pubitemid 32428766)
5. .Waxmonsky JA, Thomas MR, Miklowitz DJ, et al. Prevalence and correlates of tobacco use in bipolar disorder: data from the first 2000 participants in the Systematic Treatment Enhancement Program. Gen Hosp Psychiatry. 2005;27(5):321-328. doi:10.1016/j.genhospsych.205.05.03 PubMed (Pubitemid 41317047)
6. Diaz FJ, James D, Botts S, et al. Tobacco smoking behaviors in bipolar disorder: a comparison of the general population, schizophrenia, and major depression. Bipolar Disord. 2009;11(2):154-165. doi:10.1/j.139-5618.209.064.x PubMed
7. Gonzalez-Pinto A, Gutierrez M, Ezcurra J, et al. Tobacco smoking and bipolar disorder. J Clin Psychiatry. 1998;59(5):225-228. doi:10.408/JCP.v59n0503 PubMed (Pubitemid 28274605)
8. Covey LS, Hughes DC, Glassman AH, et al. Ever-smoking, quitting, and psychiatric disorders: evidence from the Durham, North Carolina, Epidemiologic Catchment Area. Tob Control. 1994;3(3):222-227. doi:10.136/tc.3.3.2
9. Ziedonis D, Hitsman B, Beckham JC, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res. 2008;10(12):1691-1715. doi:10.1080/1462080243569 PubMed
10. Ösby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844-850. doi:10.101/archpsyc.58.9.84 PubMed (Pubitemid 32979302)
11. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA. 2005;293(20):2528-2530. doi:10.101/jama.293.20.2528 PubMed (Pubitemid 40705735)
12. Schroeder SA, Morris CD. Confronting a neglected epidemic: tobacco cessation for persons with mental illnesses and substance abuse problems. Annu Rev Public Health. 2010;31(1):297-314, 1p, 314. doi:10.146/anurev.publhealth. 012809.103701 PubMed
13. George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry. 2002;52(1):53-61. doi:10.1016/S06-323(02)0139-2 PubMed (Pubitemid 34655556)
14. Evins AE, Cather C, Deckersbach T, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005;25(3):218-225. doi:10.1097/01.jcp. 0162802.54076.18 PubMed (Pubitemid 40685784)
15. Williams JM, Anthenelli RM, Morris CD, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012;73(5):654-660. doi:10.408/JCP.1m0752 PubMed
16. Jorenby DE, Hays JT, Rigotti NA, et al; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56-63. doi:10.101/jama.296.1.56 PubMed
17. Gonzales D, Rennard SI, Nides M, et al; Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-55. doi:10.101/jama.296.1.47 PubMed
18. Tonstad S, Tønnesen P, Hajek P, et al; Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64-71. doi:10.101/jama.296.1.64 PubMed
19. Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction. 2008;103(1):146-154. doi:10.1/j.1360-043.207.02083.x PubMed (Pubitemid 350233424)
20. Weinberger AH, Vessicchio JC, Sacco KA, et al. A preliminary study of sustained-release bupropion for smoking cessation in bipolar disorder. J Clin Psychopharmacol. 2008;28(5):584-587. doi:10.1097/JCP.0b013e318184ba3c PubMed
21. Golden RN, James SP, Sherer MA, et al. Psychoses associated with bupropion treatment. Am J Psychiatry. 1985;142(12):1459-1462. PubMed (Pubitemid 16169884)
22. Fogelson DL, Bystritsky A, Pasnau R. Bupropion in the treatment of bipolar disorders: the same old story? J Clin Psychiatry. 1992;53(12):443-446. PubMed (Pubitemid 23018088)
23. El-Mallakh RS. Bupropion manic induction during euthymia, but not during depression. Bipolar Disord. 2001;3(3):159-160. doi:10.1034/j.139-5618.201. 030305.x PubMed (Pubitemid 32611445)
24. Kotlyar M, Brauer LH, Tracy TS, et al. Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol. 2005;25(3):226-229. doi:10.1097/01.jcp. 0162805.46453.e3 PubMed (Pubitemid 40685785)
25. Hannestad JO, Cosgrove KP, Dellagioia NF. Changes in the cholinergic system between bipolar depression and euthymia as measured with [123I]5IA single photon emission computed tomography. Biol Psychiatry. 2013;74(10):768-776. PubMed
26. Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry. 2007;164(8):1269-1270. doi:10.176/api.ajp. 207.07010173 PubMed (Pubitemid 47292424)
27. Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry. 2007;164(8):1269. doi:10.176/api.ajp.207.07020326 PubMed
28. Alhatem F, Black JE. Varenicline-induced mania in a bipolar patient. Clin Neuropharmacol. 2009;32(2):117-118. doi:10.1097/WNF.0b013e31816f75bc PubMed
29. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57. PubMed
30. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. doi:10.192/bjp.134.4.382 PubMed (Pubitemid 9136500)
31. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429-435. doi:10.192/bjp.13.5.429 PubMed (Pubitemid 9006756)
32. Biener L, Abrams DB. The Contemplation Ladder: validation of a measure of readiness to consider smoking cessation. Health Psychol. 1991;10(5):360-365. doi:10.1037/0278-613.10.5.360 PubMed
33. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-1127. doi:10.1/j.1360-043.191.tb01879.x PubMed
34. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55. doi:10.1/j.204-8341.1959.tb0467.x PubMed
35. Guy W. Clinical Global Impressions Scale. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976: 217-222.
36. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277. PubMed
37. Perkins KA, Conklin CA, Levine MD. Cognitive-Behavioral Therapy for Smoking Cessation: A Practical Guide to the Most Effective Treatments. New York, NY: Routledge; 2008.
38. Wu BS, Weinberger AH, Mancuso E, et al. A preliminary feasibility study of varenicline for smoking cessation in bipolar disorder. J Dual Diagn. 2012;8(2):131-132. doi:10.1080/1504263.2012.671067 PubMed
39. Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ. 2009;339:b3805. doi:10.136/bmj.b3805 PubMed
40. Moore TJ, Furberg CD. Varenicline and suicide: risk of psychiatric side effects with varenicline. BMJ. 2009;339:b4964. doi:10.136/bmj.b4964 PubMed
41. Gunnell D, Irvine D, Wise L, et al. Authors' reply. BMJ. 2009;339:b4969. doi:10.136/bmj.b4969
42. McClure JB, Swan GE, Jack L, et al. Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J Gen Intern Med. 2009;24(5):563-569. doi:10.107/s1606-09-0926-8 PubMed
43. Murray G, Harvey A. Circadian rhythms and sleep in bipolar disorder. Bipolar Disord. 2010;12(5):459-472. doi:10.1/j.139-5618.2010.0843.x PubMed
44. Chantix [package insert]. New York, NY: Pfizer Inc; 2013
45. Williams JM, Gandhi KK, Lu S-E, et al. Nicotine intake and smoking topography in smokers with bipolar disorder. Bipolar Disord. 2012;14(6):618-627. doi:10.1/j.139-5618.2012.01047.x PubMed
46. Ostacher MJ, Nierenberg AA, Perlis RH, et al. The relationship between smoking and suicidal behavior, comorbidity, and course of illness in bipolar disorder. J Clin Psychiatry. 2006;67(12):1907-1911. doi:10.408/JCP.v67n1210 PubMed (Pubitemid 46048187)
47. Heffner JL, Strawn JR, DelBello MP, et al. The co-occurrence of cigarette smoking and bipolar disorder: phenomenology and treatment considerations. Bipolar Disord. 2011;13(5-6):439-453. doi:10.1/j.139-5618.201.0943.x PubMed
48. Heffner JL, Fleck DE, DelBello MP, et al. Cigarette smoking and impulsivity in bipolar disorder. Bipolar Disord. 2012;14(7):735-742. doi:10.1/bdi.12010 PubMed
49. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013;368(4):341-350. doi:10.1056/NEJMsa12128 PubMed
50. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368(4):351-364. doi:10.1056/NEJMsa12127 PubMed
51. Schroeder SA. New evidence that cigarette smoking remains the most important health hazard. N Engl J Med. 2013;368(4):389-390. doi:10.1056/ NEJMe1213751 PubMed
52. Issa JS, Abe TO, Moura S, et al. Effectiveness of coadministration of varenicline, bupropion, and serotonin reuptake inhibitors in a smoking cessation program in the real-life setting. Nicotine Tob Res. 2013;15(6):1146-1150. doi:10.1093/ntr/nts230 PubMed